Uganda NDA drug registration process for pharmaceutical exporters

Uganda NDA Drug Registration 2026: Complete Guide & IVDs

NDA Uganda · Registration Guide for Exporters

Uganda NDA Drug Registration Process: The Exporter’s Guide to Marketing Authorization & Import Licensing

Updated 3 October 2026 · Added: IVD & medical-device route, 2026 law change, EAC membership correction

Getting a medicine legally onto the Ugandan market runs on three parallel tracks — a Marketing Authorization for each product from the National Drug Authority (NDA), a Uganda-based Local Technical Representative who holds it, and a per-shipment import permit to move it across the border. This guide walks through all three using NDA’s own published service standards, shows how a Kenya PPB dossier becomes the fastest route in, and explains how the separate IVD and medical-device route differs.

National Drug Authority (NDA) CTD Dossier EAC-MRH For India-based Exporters IVDs: separate device route
US$507MUganda’s total pharmaceutical imports, 2023 [1]
18 moNDA service standard, human-medicine assessment [2]
6 moDecision standard for WHO-PQ / SRA-approved products [2]
5-yrCertificate of Registration validity [3]

What it actually takes to sell a medicine in Uganda

You need three things in place. First, Marketing Authorization from the National Drug Authority (NDA) for each product — filed as a CTD dossier through a Uganda-based Local Technical Representative (LTR), since a foreign manufacturer cannot apply directly. Second, your Ugandan partner’s own premises and import licensing to legally receive and distribute the product. Third, a per-consignment import permit, verified by NDA before customs release. Under NDA’s published service standards, budget up to 18 months for a standard human-medicine assessment — or as little as 6 months if the product already carries WHO-Prequalification or Stringent Regulatory Authority (SRA) approval.[2]

Registering a test kit or other IVD instead? That is a medical-device registration, not a medicine CTD — different law, risk classes A–D and three reference-approval tracks. Jump to the IVD route.

01 · Market Context

Why Uganda is the natural second market after Kenya

Uganda is landlocked: most of its imports, pharmaceuticals included, move overland from the port of Mombasa through Kenya along the Northern Corridor. For an exporter who already has a Kenyan PPB relationship, Uganda is an adjacent next step rather than a fresh start — the logistics route, the regional regulatory framework and much of the dossier carry over from a WHO-GMP manufacturing base.

Uganda’s total pharmaceutical imports were valued at US$507.12 million in 2023 (UN Comtrade).[1] India-origin pharmaceutical imports into Uganda are reported at US$246.2 million in Uganda’s own 2023 import data,[4] against US$102.75 million in India’s 2024 export data for the same lane[5] — a mirror-statistics gap that is common between two countries’ customs records (re-exports, valuation basis and timing all differ). Even on the conservative figure, India is a substantial supplier to the Ugandan market.

NDA also publishes explicit service-delivery timelines for each stage of product assessment — more process transparency than most East African regulators offer, and the basis for the timelines in this guide. Those standards include a genuine reliance pathway: products already WHO-Prequalified, approved by a Stringent Regulatory Authority, or authorised under Article 58 of EU rules get a 6-month decision standard instead of the 18-month standard track.[2]

What changed in 2026 — a new regulator law. Uganda’s Parliament passed the National Drug and Health Products Authority Bill, 2025 on 26 March 2026, replacing the 1993 framework and widening the regulator’s remit to vaccines, diagnostics, biologicals, medical devices, cosmetics, public health products and nutritional supplements; it also introduces mandatory lot release for vaccines, biologicals and diagnostics.[6] The President’s assent was reported on 29 April 2026.[7]

What we could not confirm: the commencement date, and the transition rules for registrations already granted. Until NDA publishes them, NDA’s existing guidelines and online portal remain the working route — confirm with your LTR before filing.

The strategic read: Uganda sits inside the same East African Community Medicines Regulatory Harmonization (EAC-MRH) framework as Kenya. A CTD dossier built to PPB standard is largely reusable here — mainly Module 1 (local administrative content) changes. Treat Uganda as the second stop on a regional platform, not a standalone build — see our PPB Kenya drug registration process guide for the first stop.
02 · The Core Distinction

The three approvals you’re actually chasing

As in Kenya, “getting registered in Uganda” is not one approval — it is three workstreams on different clocks. Confuse them and you end up with a registered product that has nowhere licensed to land it, or a licensed importer with nothing approved to bring in.

TrackWhat it isHandled at NDA by
1 · Marketing AuthorizationProduct-specific approval, assessed on quality, safety and efficacy from a full CTD dossierProduct assessment & registration
2 · LTR & premises / import licensingYour Ugandan partner’s own licensing to legally receive and distribute productInspectorate & enforcement
3 · Import permitPer-consignment clearance once the product and the importer are both approvedImports & exports function

Scroll sideways to see the full table →

Marketing Authorization, in detail

What it is: legal permission for a specific product to be sold in Uganda, assessed on quality, safety and efficacy from a full CTD dossier submitted through NDA’s online system.

Who holds it: a foreign manufacturer cannot apply directly. You appoint a Uganda-based Local Technical Representative (LTR); NDA corresponds with, and issues the certificate through, that representative.

Timeline & validity: the standard human-medicine review-and-query cycle carries an 18-month (396 working-day) service standard, plus 3 months (66 working days) for the regulatory decision once you have answered NDA’s queries. WHO-Prequalified or SRA-approved products qualify for a 6-month (132 working-day) decision standard instead.[2] The certificate is valid five years under Regulation 40(1) of the National Drug Policy and Authority (Registration) Regulations, 2014.[3]

The sequencing trap: Marketing Authorization is the long pole in the tent, so start it first. Run the LTR/importer relationship (Track 2) in parallel — a registered product with nowhere licensed to receive it stalls at the border. The import permit (Track 3) only matters once the first two are secured.

03 · Division of Responsibility

Who does what: manufacturer vs. Ugandan LTR

For an India-based exporter, the workload splits cleanly between what you supply from the plant and what your Ugandan LTR handles on the ground.

ResponsibilityManufacturer / exporter (India)Local Technical Representative (Uganda)
CTD dossier (Modules 1–5)Compiles quality, safety & efficacy data; CMC, stability & batch dataAdapts Module 1 (local admin) & submits via NDA’s online system
Certificate of Pharmaceutical ProductObtains WHO-format CoPP from CDSCO / the licensing authorityFiles it with the application
GMP evidenceSupplies WHO-GMP certificate, site master file, WHO-PQ / SRA record if heldCoordinates any NDA GMP inspection — foreign-site inspections carry a 180 working-day standard[2]
Local Technical RepresentativeAppoints the LTRActs as NDA’s correspondence point; holds the registration paperwork
Premises & import licensing—Holds the licensed premises and import licence NDA requires
Import permitsProvides invoice, CoA, packing docs per shipmentApplies for the permit — NDA verification 3 working days, port clearance 2 working days, once registered[2]
PharmacovigilanceSupplies PSURs & safety dataRuns local ADR reporting — NDA’s standard is 5 days to acknowledge, 18 days to feedback on serious cases[2]

Scroll sideways to see the full table →

Where a WHO-GMP manufacturer changes the math: if you are a brand owner or distributor without your own approved plant, sourcing from a WHO-GMP third-party manufacturing partner means the CoPP, GMP certificate, site master file, stability data and CoA in the left column arrive as a ready package. If that plant already holds WHO-PQ or SRA approval, it is also the single biggest lever on whether your file gets the 6-month reliance track or the 18-month standard track. Our third-party manufacturing for African markets guide covers how that arrangement is typically scoped, and the pharmaceutical export documentation checklist lists which certificate each African regulator actually asks for.

04 · The Process

Registration, step by step

NDA’s stages are well defined and published against explicit day-counts. Getting through them without avoidable delay is mostly about dossier quality and query-response speed — not obscure steps.

  1. Pre-submission preparation

    Appoint your LTR, confirm current NDA dossier requirements, and establish whether your site’s WHO-GMP status also carries WHO-PQ or SRA recognition — the biggest determinant of which timeline track applies.

  2. Dossier compilation

    Build the full CTD across Modules 1–5 in the EAC-harmonised ICH format. Consistency between modules is the most common trigger for deficiency queries later.

  3. Application submission

    Submit through NDA’s online application system via your LTR, and pay the applicable statutory fees.

  4. Screening & validation

    NDA checks the application is complete and correctly formatted before it enters scientific review. Missing documentation stops the process here.

  5. Scientific assessment

    Standard track: 18 months (396 working days). Reliance track (WHO-PQ / SRA / Article 58 EU-approved products): 6 months (132 working days). A stop-clock applies — the count pauses whenever NDA issues a query and resumes once you respond.[2]

  6. GMP review or inspection

    Foreign-site physical inspections carry a 180 working-day service standard.[2] Recognised WHO-PQ / SRA status can allow reliance in place of a fresh inspection, saving months.

  7. Query response & decision

    Answer deficiency queries within the window given — the clock stays paused while NDA waits on you. Regulatory decision after complete information is received: 3 months (66 working days).[2]

  8. Registration certificate issued

    On approval, a Certificate of Registration is issued, valid five years.[3] Pharmacovigilance obligations begin immediately.

05 · Documentation

The CTD dossier — and what “complete” really means

NDA accepts the ICH Common Technical Document (CTD) format under the EAC-harmonised structure — the same requirement set covered in our Kenya PPB guide, with mainly Module 1 (local administrative content) changing per country. That is what makes a Kenyan dossier reusable here.

RequirementWhat it proves
Local Technical RepresentativeYour correspondence and regulatory point of contact inside Uganda
Certificate of Pharmaceutical Product (CoPP)Approval status in the country of origin (WHO format)
GMP certificate / evidenceManufacturing site meets recognised quality standards
CTD dossier (Modules 1–5)Core quality, safety & efficacy documentation
Certificate of Analysis (CoA)Batch-level product quality against specification
Stability dataSupports shelf-life & storage claims for the hot, humid climatic zone
Product labeling & package insertUganda-compliant labeling
Interchangeability / BE data (generics)Therapeutic equivalence, per Module 5
Patent declarationIntellectual-property status

Scroll sideways to see the full table →

Stability claims are where Indian files most often get queried — our guide to climate-zone-stable packaging for export covers the pack choices that support them.

Interactive · Dossier readiness check

0% ready · 0 / 9

Indicative checklist for planning only. Nothing is stored or sent — it runs entirely in your browser. Confirm the current requirement set against official NDA guidelines before you file.

06 · Budgeting

Fees & the registration planner

NDA sets statutory fees by its current tariff and product category. We could not source an official published fee table for this guide, so treat the figures below as planning assumptions, not quoted amounts. What is verifiable is the structure — the cost lines you will meet:

Cost lineWhen it appliesNotes
Application / registration feePer product, at submissionIndicative US$1,000–1,500 per product, per public planning guidance from a Kenya/Uganda regulatory consultancy[8] — not an NDA-published figure
GMP inspection feeIf NDA inspects an un-assessed foreign siteForeign inspection carries a 180 working-day service standard;[2] often avoidable via WHO-PQ / SRA reliance
Annual retentionYearly, to keep registration liveRecurring across the 5-year validity
Variation feePost-approval changesMinor variation: 4-month decision standard. Major variation (no physical verification): 6-month standard[2]
Renewal feeEvery 5 yearsFile ahead of expiry
LTR retainerOngoing (commercial, not NDA)Negotiated with your Local Technical Representative

Scroll sideways to see the full table →

Interactive · NDA registration planner

Upfront NDA fees—
Year-1 total (incl. LTR)—
Annual carrying cost—
Est. timeline—

Illustrative only, in indicative US$. Excludes dossier preparation, CoPP / legalisation, lab analysis, freight and taxes. Default rates are planning placeholders, not official NDA figures — verify every input with NDA and your LTR. Not financial advice.

07 · Expectations

Two realistic timelines, not one

Because NDA publishes its own day-counts, an exporter can plan against two clearly different paths rather than a single vague estimate. Months below count from the day you start preparing the file, at full service standard.

Standard track — WHO-GMP only
Preparation & submissionMonths 0–3
Scientific assessment~18 mo (396 days)
GMP foreign inspection (parallel)~180 days
Decision after query response~3 mo (66 days)
Certificate issued (worst case)~Month 21–24
Reliance track — WHO-PQ / SRA
Preparation & submissionMonths 0–3
Assessment & decision~6 mo (132 days)
GMP inspectionOften replaced by reliance
Certificate issued~Month 6–9

What blows the timeline: inconsistencies between CTD modules, unrecognised GMP status (which triggers the 180-day foreign inspection instead of reliance), and slow query responses — the stop-clock keeps the review paused while the ball is in your court.[2]

08 · Regional Leverage

EAC-MRH: register once, expand across East Africa

Uganda participates in the East African Community Medicines Regulatory Harmonization (EAC-MRH) programme, launched on 30 March 2012 to align registration requirements, assessment standards and post-market surveillance across EAC Partner States.[9] The EAC itself now has eight Partner States — Burundi, DR Congo, Kenya, Rwanda, Somalia, South Sudan, Tanzania and Uganda — after Somalia formally joined on 4 March 2024.[10]

Harmonization mechanismWhat it means for your submission
Common CTD formatOne dossier structure accepted across partner states — mainly Module 1 changes per country
Mutual recognition of GMP reportsA GMP inspection outcome can be recognised across the bloc, reducing repeat inspections
Joint assessmentProducts seeking multi-country registration can be reviewed collaboratively
Aligned classification & labelingProgressively common rules cut per-market rework

Scroll sideways to see the full table →

The practical play: register in Kenya first, then reuse the CTD core for Uganda (NDA), adjusting the local administrative content. Tanzania and Rwanda are the next extensions of the same dossier — see our Tanzania TMDA drug registration process and Rwanda FDA drug registration process guides, the latter covering the abbreviated EAC procedure. This is why Kenya-then-Uganda is a regional platform, not two standalone builds — the same logic behind our pharmaceutical export to Africa approach.

09 · IVDs & Medical Devices

Uganda NDA IVD registration: how the device route differs from medicines

Short answer: NDA regulates in vitro diagnostics through its medical-device framework, not the medicine CTD route above. Devices are registered under Statutory Instrument No. 77 of 2019 (the Surgical Instruments and Appliances Regulations) and a ministerial decree of 20 July 2020, sorted into four risk classes from Class A (lowest) to Class D (highest), and reviewed on one of three tracks depending on prior reference approval.[11] WHO’s model regulatory framework treats IVDs as a category of medical device,[12] and Uganda’s 2026 law names diagnostics explicitly within the regulator’s remit.[6]

Point of differenceMedicines (this guide)IVDs & medical devices
Legal basisNational Drug Policy and Authority Act and the 2014 Registration Regulations[3]SI No. 77 of 2019 (Surgical Instruments and Appliances) + ministerial decree ADM.140/323/01, 20 July 2020[11]
How products are sortedBy product and dossier typeRisk-based Class A, B, C or D[11]
Fast routeReliance for WHO-PQ / SRA / Article 58 products — 6-month decision standard[2]Track 1: approved in an IMDRF country · Track 2: WHO-prequalified or registered in an SRA country · Track 3: no reference approval[11]
DossierEAC-harmonised CTD, Modules 1–5Device technical documentation per NDA’s guideline on registration of surgical instruments and appliances — not a medicine CTD
LicencesMarketing Authorization + premises + import permitDevice registration + manufacturer, wholesale and import-permit licences, applied for on NDA’s portal[11]
Published day-countsYes — the timelines used throughout this guide[2]Not stated on NDA’s devices page; NDA says reference-market approvals bring shorter, expedited reviews[11]
Post-marketPharmacovigilance / ADR reportingAdverse-event reporting, plus lot release for diagnostics under the 2026 law once in force[6]

Scroll sideways to see the full table →

What NDA has — and has not — published on IVDs (checked 3 October 2026):

  • NDA’s medical-devices page sets out the classes, tracks, licences and legal basis above, and lists guidelines on registration of surgical instruments and appliances, GMP for surgical instruments and appliances, and medical face masks.[11]
  • That page does not use the terms “IVD” or “in vitro diagnostic”, and we found no IVD-specific dossier guideline on NDA’s devices pages — which is why IVD dossier questions are best put to NDA directly.
  • Before compiling an IVD file, ask NDA’s medical-devices team in writing which classification rules and technical-file structure apply to your kit. If the kit is WHO-prequalified, Track 2 is the strongest position you can file from.

Interactive · Which Uganda route applies to your product?

1. What are you registering?

2. What approval does it already hold?

Answer both questions to see your route

The route decides the law, the dossier format and the timeline you plan against.

A straight word on scope: Puizer Cure manufactures and exports finished medicines. We do not supply IVDs or medical devices, so if your portfolio is diagnostics only, NDA’s medical-devices team and a device-specialist LTR are the right first contacts. If you are registering medicines alongside kits, the three medicine approvals above are where we can help — starting with dossier-ready products for East Africa.

10 · Risk Management

Common delay triggers — and how to avoid them

  • Weak or missing stability data. Make sure data supports the claimed shelf life under the correct climatic zone before filing.
  • Inconsistency between CTD modules. Figures or claims that do not reconcile across Modules 1–5 generate deficiency queries.
  • An unrecognised or absent GMP status. A site NDA has not assessed, with no WHO-PQ / SRA record to rely on, triggers the 180 working-day physical inspection instead of the reliance track.
  • Treating the LTR as a formality. The representative is a legal correspondence role, not a mailbox. A weak or unresponsive LTR slows every query cycle.
  • Slow query responses. The stop-clock keeps the timeline paused while NDA waits on you — resource the response function before you file, not after.
  • Registering the product but not the import route. A live registration with no licensed importer to receive shipments leaves stock stuck at the border.
  • Filing a device as a medicine (or the reverse). Combination portfolios need both routes; a test kit in a medicine CTD wastes a review cycle.

Sequencing multiple products: lead with SKUs that have the clearest commercial case or fill a genuine gap in Ugandan supply. Registering a whole catalogue at once multiplies fees and query load without multiplying early revenue.

Planning a Uganda or East Africa launch? Start from a WHO-GMP base.

Whether you need a registration-ready dossier package, a WHO-GMP manufacturing partner, or export documentation built to clear NDA review, our team supports importers, brand owners and Indian manufacturers entering African markets end to end.

11 · FAQ

NDA Uganda registration — frequently asked questions

Darshan Singh

Reviewed by Darshan Singh

23+ years in pharmaceutical Quality Assurance, Quality Control and Drug Regulatory Affairs. This guide is written for exporting manufacturers, importers and brand owners and reflects hands-on experience with CTD dossiers, GMP compliance and multi-market registration. It is general information, not regulatory or legal advice for a specific product.

Regulatory requirements, fees and timelines described here are indicative and change over time — Uganda’s regulator law itself changed in 2026. Always verify the current position against official National Drug Authority guidance and your appointed Local Technical Representative before acting. This is technical and educational content; nothing on this page constitutes legal, regulatory, medical or financial advice.
Sources
  1. UN Comtrade, via Trading Economics. Uganda imports of pharmaceutical products. Available from: tradingeconomics.com/uganda/imports/pharmaceutical-products. Accessed August 2026.
  2. National Drug Authority (Uganda). Service delivery timelines (Client Charter). Kampala: NDA. Available from: nda.or.ug/service-delivery-timelines. Accessed August 2026; re-check on 3 October 2026 was blocked by the site’s bot verification.
  3. The National Drug Policy and Authority (Registration) Regulations, 2014, Regulation 40(1) — certificate of registration validity. Uganda. Cited via secondary compilation; verify against the Uganda Legal Information Institute (ulii.org) or NDA before relying on it for a filing decision.
  4. UN Comtrade, via Trading Economics. Uganda imports from India, by product. Available from: tradingeconomics.com/uganda/imports/india. Accessed August 2026.
  5. UN Comtrade, via Trading Economics. India exports of pharmaceutical products to Uganda. Available from: tradingeconomics.com/india/exports/uganda/pharmaceutical-products. Accessed August 2026.
  6. Parliament of Uganda. Parliament passes sweeping reforms on medicines. Kampala: Parliament of Uganda; 27 March 2026. Available from: parliament.go.ug/news/4323. Accessed October 2026.
  7. Nile Post. Museveni signs landmark law establishing National Drug and Health Products Authority. Kampala: Nile Post; 29 April 2026. Available from: nilepost.co.ug/health/338325. Accessed October 2026. Secondary (press) source.
  8. The Pharma Partner. Product registration in Uganda (NDA). Indicative fee guidance only — not an official NDA source. Available from: thepharmapartner.co.ke/regulatory/uganda-nda-registration. Accessed August 2026.
  9. AUDA-NEPAD, African Medicines Regulatory Harmonisation (AMRH). Uganda country profile. Available from: amrh.nepad.org/amrh-countries/uganda. Accessed August 2026.
  10. East African Community. Somalia finally joins EAC as the bloc’s 8th Partner State. Arusha: EAC Secretariat; March 2024. Available from: eac.int/press-releases/3049. Accessed October 2026.
  11. National Drug Authority (Uganda). Medical devices. Kampala: NDA. Available from: nda.or.ug/medical-devices. Accessed 3 October 2026.
  12. World Health Organization. WHO global model regulatory framework for medical devices including in vitro diagnostic medical devices. Geneva: WHO; 2017. Available from: who.int/publications/i/item/9789241512350. Accessed October 2026.
Darshan Singh
Darshan Singh

Darshan Singh is a professional pharmaceutical blogger from India with over 20 years of extensive experience in the pharmaceutical industry. He holds a Master of Science degree in Chemistry, which he earned in 2003 from Kurukshetra University Kurukshetra. Pursued Diploma in Pharmacy from Haryana State Board of Technical Education

Articles: 31